Use of antiosteoporotic drugs and calcium/vitamin D in patients with fragility fractures: impact on re-fracture and mortality risk
To evaluate the impact of pharmacological treatment in osteoporosis patients with recent fracture and to assess the incidence of subsequent fracture and all-cause mortality.
This observational retrospective study was based on data from administrative databases of five Italian Local Health Units. Osteoporosis patients aged ≥ 50 years with hospitalization for vertebral or hip fracture occurring between 01/01/2011 and 31/12/2015 were included. Treatment adherence was calculated using the medication possession ratio. Multivariable proportional hazard Cox model was used to identify factors associated with time to re-fracture and all-cause mortality.
A cohort of 3475 patients were included and 41.5% of them did not receive any specific anti-fracture treatment. Among treated patients (N = 2032), the majority (83.6%) received calcium/vitamin D supplementation. Over a mean follow-up of 3 years, the risk of subsequent fractures was 44.4% lower in treated patients compared to untreated ones (HR = 0.556, 95% CI = 0.420–0.735, p < 0.001) and 64.4% lower in those receiving calcium/vitamin D supplementation compared to osteoporosis treatment only (HR = 0.356, 95% CI = 0.237-0.533, p < 0.001). The risk of re-fracture was 77.2% lower in treated patients who were adherent to medication (HR = 0.228, 95% CI = 0.139–0.376, p < 0.001). Treated patients had 64% lower mortality risk over the follow-up compared to untreated ones (HR = 0.360, 95% CI = 0.310–0.418, p < 0.001).
A consistent proportion of osteoporosis patients did not receive specific treatment after a fracture, showing poor adherence to national guidelines on osteoporosis treatment. Osteoporosis drug treatment, and to a greater extent in combination with calcium/vitamin D, and adherence were correlated with lower risk of both re-fracture and all-cause mortality.
KeywordsOsteoporosis Calcium/vitamin D Treatment patterns Re-fracture risk Clinical setting
We would like to thank all participants who took part in this study.
on the behalf of the Study group:
A. Vercellone5 and E. Nava5, F. Ferrante6, C. Bianchi6, S. Crescenzi6, P. F. Venditti6, M. Folcatrelli6, A. Constantini7, C. Cattaruzzi8
This study was sponsored unconditionally by Abiogen Pharma S.p.A, Pisa, Italy.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 1.Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med. 1993 Jun;94(6):646–50.Google Scholar
- 2.WHO Scientific Group Technical Report. Assessment of osteoporosis at the primary health care level [Internet]. 2007. Available from: https://www.sheffield.ac.uk/FRAX/pdfs/WHO_Technical_Report.pdf
- 4.Ministero della Salute-Salute della donna. Osteoporosi [Internet]. [cited 17 Jul 2018]. Available from: http://www.salute.gov.it/portale/donna/dettaglioContenutiDonna.jsp?lingua=italiano&id=4491&area=Salute%20donna&menu=patologie
- 6.M.H. Murad, M.T. Drake, R.J. Mullan, K.F. Mauck, L.M. Stuart, M.A. Lane et al. Clinical review. Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis. J. Clin. Endocrinol. Metab. 97(6), 1871–1880 (2012)CrossRefPubMedCentralGoogle Scholar
- 17.J. Reginster, H.W. Minne, O.H. Sorensen, M. Hooper, C. Roux, M.L. Brandi et al Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos. Int. 11(1), 83–91 (2000)CrossRefPubMedCentralGoogle Scholar
- 20.R. Bouillon, C. Marcocci, G. Carmeliet. Skeletal and extra-skeletal actions of vitamin D: Current evidence and outstanding questions. Endocr. Rev. [Internet]. 12, 2018;12. Available from: https://www.ncbi.nlm.nih.gov/pubmed/30321335
- 21.A. Giustina, R. Adler, N. Binkley. Controversies in vitamin D: Summary statement from an international conference. J Clin Endocrinol Metab [Internet]. 31, 2018. Available from: https://www.ncbi.nlm.nih.gov/pubmed/30383226
- 24.Agenzia Italiana del Farmaco (AIFA). Nota 79-Prescription of osteoporosis medications at risk of fragility fracture or subsequent fracture [Internet]. Available from: http://www.gazzettaufficiale.it/eli/id/2015/05/20/15A03762/sg
- 26.C. Cipriani, J. Pepe, F. Bertoldo, G. Bianchi, F.P. Cantatore, A. Corrado et al. The epidemiology of osteoporosis in Italian postmenopausal women according to the National Bone Health Alliance (NBHA) diagnostic criteria: a multicenter cohort study. J. Endocrinol. Invest. 41(4), 431–438 (2018)CrossRefPubMedCentralGoogle Scholar
- 27.R. Halpern, L. Becker, S.U. Iqbal, L.E. Kazis, D. Macarios, E. Badamgarav, The association of adherence to osteoporosis therapies with fracture, all-cause medical costs, and all-cause hospitalizations: a retrospective claims analysis of female health plan enrollees with osteoporosis. J. Manag. Care Pharm. 17(1), 25–39 (2011)PubMedPubMedCentralGoogle Scholar
- 31.P. Vestergaard, L. Rejnmark, L. Mosekilde, Fracture risk associated with different types of oral corticosteroids and effect of termination of corticosteroids on the risk of fractures. PubMed-Ncbi. 4(82), 249–257 (2008)Google Scholar